Cite

HARVARD Citation

    Bishop, M. et al. (2020). A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors. MAbs. 12 (1), p. . [Online]. 
  
Back to record